The CDC’s restricted communication under HHS oversight has hindered public awareness amid rising global disease outbreaks ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The U.S. Centers for Disease Control and Prevention accepted its advisory panel's recommendations on vaccines for chikungunya ...

The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

Mosquitoes can tranmist dengue virus, which has already caused local cases in Florida in 2025... | Clinical And Molecular Dx ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

About 200 cases of chikungunya were reported in the U.S. in 2024; all of them were travel-associated. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) ...